The text appears to be a series of interviews or responses from Sarah Guo, an investor in the biotech and AI space, as well as other experts and founders. The topics covered include:
- The impact of Y Combinator’s presence on early-stage valuations
- Due diligence changes in 2022
- Big Pharma’s interaction with biotech startups
- Potential effects of US sanctions on China on AI-enabled biotech startups
- Interest in cold pitches from founders
Some key quotes and takeaways:
- Sarah Guo mentions that due diligence has become more critical, especially in domains like healthcare, where "confidence in a team’s risk management and ethics is critical."
- She notes the importance of understanding the domain and the founder’s vision when making investments.
- In response to US sanctions on China, Sarah suggests that there are real security risks to consider, which may lead to reduced access to global state-of-the-art care for startups.
- Big Pharma tends to innovate through partnerships with biotechs before acquiring them.
The text also mentions other topics such as:
- Colossal Biosciences raising $200M at a $10.2B valuation
- Teal Health raising $10M for at-home cervical cancer screenings
- Bluesky developing its own photo-sharing app, Flashes